Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Isobaric labeling of biospecimens followed by mass spectrometry (MS) has become the method of choice for large-scale, untargeted, quantitative proteomic profiling. However, subtle variation in experimental conditions can amplify sample variability and introduce systematic biases. Motivated by the challenges and opportunities arose in a recent proteogenomic study, we developed ProMix, a flexible analytical framework designed to improve protein normalization by leveraging two key experimental design features: (1) the inclusion of an additional reference sample to serve as an internal standard, and (2) the incorporation of replicates of each specimen. ProMix can utilize either or both features. Through applications to both simulated and real data sets, we demonstrate the improved performance of ProMix and highlight the advantages of the enhanced experimental design strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12364727 | PMC |
| http://dx.doi.org/10.1021/acs.jproteome.4c01108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Toward Human-Centered Artificial Intelligence for Users' Digital Well-Being: Systematic Review, Synthesis, and Future Directions.
JMIR Hum Factors
September 2025
Seidenberg School of Computer Science and Information Systems, Pace University, New York City, NY, United States.
Background: As information and communication technologies and artificial intelligence (AI) become deeply integrated into daily life, the focus on users' digital well-being has grown across academic and industrial fields. However, fragmented perspectives and approaches to digital well-being in AI-powered systems hinder a holistic understanding, leaving researchers and practitioners struggling to design truly human-centered AI systems.
Objective: This paper aims to address the fragmentation by synthesizing diverse perspectives and approaches to digital well-being through a systematic literature review.
A Risk Prediction Tool for Invasive Melanoma.
JAMA Dermatol
September 2025
Department of Population Health, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Importance: Increasingly, strategies to systematically detect melanomas invoke targeted approaches, whereby those at highest risk are prioritized for skin screening. Many tools exist to predict future melanoma risk, but most have limited accuracy and are potentially biased.
Objectives: To develop an improved melanoma risk prediction tool for invasive melanoma.
High-Intensity Exercise and Hippocampal Integrity in Adults With Cannabis Use Disorder: A Randomized Clinical Trial.
JAMA Psychiatry
September 2025
School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia.
Importance: Cannabis is the most commonly used illicit drug, with 10% to 30% of regular users developing cannabis use disorder (CUD), a condition linked to altered hippocampal integrity. Evidence suggests high-intensity interval training (HIIT) enhances hippocampal structure and function, with this form of physical exercise potentially mitigating CUD-related cognitive and mental health impairments.
Objective: To determine the impact of a 12-week HIIT intervention on hippocampal integrity (ie, structure, connectivity, biochemistry) compared with 12 weeks of strength and resistance (SR) training in CUD.
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial.
JAMA
September 2025
Division of Surgery and Interventional Science, UCL, London, United Kingdom.
Importance: Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.
View Article and Find Full Text PDFANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression: The ENLIGHTEN Randomized Clinical Trial.
JAMA Psychiatry
September 2025
Denovo Biopharma LLC, San Diego, California.
Importance: This study represents a first successful use of a genetic biomarker to select potential responders in a prospective study in psychiatry. Liafensine, a triple reuptake inhibitor, may become a new precision medicine for treatment-resistant depression (TRD), a major unmet medical need.
Objective: To determine whether ANK3-positive patients with TRD benefit from a 1-mg and/or 2-mg daily oral dose of liafensine, compared with placebo, in a clinical trial.